Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis

被引:4
|
作者
Gao, Fenghua [1 ]
Zhang, Tingting [1 ]
Liu, Hengqi [1 ]
Li, Wei [1 ]
Liu, Xianming [1 ]
Qiu, Lihua [1 ]
Li, Lanfang [1 ]
Zhou, Shiyong [1 ]
Qian, Zhengzi [1 ]
Dong, Sitong [2 ]
Zhao, Sai [2 ]
Wang, Xianhuo [1 ]
Zhang, Huilai [1 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Dept Lymphoma, Sino US Ctr Lymphoma & Leukemia Res,Key Lab Canc, Huanhuxi Rd, Tianjin 300060, Peoples R China
[2] Systemat Review Solut Ltd, Ingenu Ctr, Nottingham, England
基金
中国国家自然科学基金;
关键词
Follicular lymphoma; POD24; Risk factors; Meta-analysis; Systematic review; SOLUBLE INTERLEUKIN-2-RECEPTOR LEVEL; METABOLIC TUMOR VOLUME; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; PROGRESSION-FREE SURVIVAL; MINIMAL RESIDUAL DISEASE; PROGNOSTIC VALUE; 1ST-LINE TREATMENT; PREDICTS SURVIVAL; DIAGNOSIS; DOXORUBICIN;
D O I
10.1007/s00277-022-04914-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Progression of disease within 24 months (POD24) is strongly associated with a poor outcome in patients with follicular lymphoma (FL). Our study aimed to identify the potential risk factors for POD24 in patients with FL. Medline, EMBASE and the Cochrane Library were systematically searched from the earliest record to September 2020. Studies investigating the prognostic factors for POD24 in patients with newly diagnosed grade 1-3a FL were included. Among 10,014 pieces of literature, a total of 90 studies investigating 82 risk factors were included for qualitative analysis. Meta-analyses were performed in 31 studies with 11 factors. Results showed that elevated sIL-2R, beta 2m and LDH, total metabolic tumour volume > 510 cm(3), vitamin D < 20 ng/mL, grade 3a and lymphoma-associated macrophages/high-power field >= 15 were significantly associated with an increased risk of POD24. No significant association was found between POD24 and the ALC/AMC ratio, sex, T effector signature or EZH2 genetic alteration. Additionally, minimal residual disease, Ki-67, PD-1 and TP53 were analysed narratively. Overall, this is the first study that comprehensively analysed the prognostic factors associated with POD24 in FL patients. We have confirmed the significance value of several common prognostic factors as well as others not commonly included in clinical study, helping to construct an integrated and more efficient model.
引用
收藏
页码:2383 / 2392
页数:10
相关论文
共 50 条
  • [1] Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis
    Fenghua Gao
    Tingting Zhang
    Hengqi Liu
    Wei Li
    Xianming Liu
    Lihua Qiu
    Lanfang Li
    Shiyong Zhou
    Zhengzi Qian
    Sitong Dong
    Sai Zhao
    Xianhuo Wang
    Huilai Zhang
    Annals of Hematology, 2022, 101 : 2383 - 2392
  • [2] Correction to: Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta‑analysis
    Fenghua Gao
    Tingting Zhang
    Hengqi Liu
    Wei Li
    Xianming Liu
    Lihua Qiu
    Lanfang Li
    Shiyong Zhou
    Zhengzi Qian
    Sitong Dong
    Sai Zhao
    Xianhuo Wang
    Huilai Zhang
    Annals of Hematology, 2022, 101 : 2817 - 2817
  • [3] Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis (vol 101, pg 2383, 2022)
    Gao, Fenghua
    Zhang, Tingting
    Liu, Hengqi
    Li, Wei
    Liu, Xianming
    Qiu, Lihua
    Li, Lanfang
    Zhou, Shiyong
    Qian, Zhengzi
    Dong, Sitong
    Zhao, Sai
    Wang, Xianhuo
    Zhang, Huilai
    ANNALS OF HEMATOLOGY, 2022, 101 (12) : 2817 - 2817
  • [4] A Systematic Literature Review and Meta-Analysis of Radioimmunotherapy Consolidation for Patients With Untreated Follicular Lymphoma
    Rose, Adam C.
    Shenoy, Pareen J.
    Garrett, Gia
    Seward, Miray
    Kucuk, Roy A.
    Doksansky, Hannah
    Nastoupil, Loretta J.
    Flowers, Christopher R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (06): : 393 - 399
  • [5] A Systematic Review and Meta-Analysis of Radioimmunotherapy Consolidation for Untreated Patients with Follicular Lymphoma (FL)
    Rose, Adam C.
    Garrett, Gia
    Seward, Miray
    Shenoy, Pareen T.
    Kucuk, Roy A.
    Doksansky, Hannah
    Flowers, Christopher R.
    BLOOD, 2011, 118 (21) : 49 - 49
  • [6] Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma
    Wu, Wei
    Bruscaggin, Alessio
    Valera, Alexandra
    Flospergher, Elena
    Bonfiglio, Ferdinando
    Spina, Valeria
    Terzi-Di-Bergamo, Lodovico
    Moccia, Alden
    Moia, Riccardo
    Ruffini, Alessia
    Stathis, Anastasios
    Faderl, Martin
    Koch, Ricardo
    Forestieri, Gabriela
    Pini, Katia
    Condoluci, Adalgisa
    Pirosa, Maria Cristina
    Gerber, Bernhard
    Gillessen, Silke
    Stussi, Georg
    Ghielmini, Michele
    Cavalli, Franco
    Luminari, Stefano
    Boldorini, Renzo
    Mazzucchelli, Luca
    Gaidano, Gianluca
    Rossi, Davide
    Zucca, Emanuele
    BLOOD, 2020, 136
  • [7] REAL-LIFE IMPACT OF THE POD24 INDICATOR IN PATIENTS WITH FOLLICULAR LYMPHOMA
    Noguerales Blanca, De Felipe
    de Abia Alejandro, Luna
    Arribas Ana, Lario
    Rumschisky Pablo, Palomo
    Jarreta Lucia, Bolea
    Palomares Juan, Marquet
    Moro Fernando, Martin
    Cosio Monica, Garcia
    Puente Pilar, Herrera
    Francisco Javier, Lopez Jimenez
    HAEMATOLOGICA, 2021, 106 (10) : 49 - 49
  • [8] A systematic review and meta-analysis of occupational exposures and risk of follicular lymphoma
    Odutola, Michael K.
    Benke, Geza
    Fritschi, Lin
    Giles, Graham G.
    van Leeuwen, Marina T.
    Vajdic, Claire M.
    ENVIRONMENTAL RESEARCH, 2021, 197
  • [9] A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma
    Hicks, Lisa K.
    Haynes, Adam E.
    Reece, Donna E.
    Walker, Irwin R.
    Herst, Jordan A.
    Meyer, Ralph M.
    Imrie, Kevin
    CANCER TREATMENT REVIEWS, 2008, 34 (05) : 442 - 452
  • [10] Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma
    Zha, Jie
    Chen, Qinwei
    Zhang, Wei
    Jing, Hongmei
    Ye, Jingjing
    Yu, Haifeng
    Yi, Shuhua
    Li, Caixia
    Zheng, Zhong
    Xu, Wei
    Li, Zhifeng
    Ping, Lingyan
    He, Xiaohua
    Zhang, Liling
    Xie, Ying
    Chen, Feili
    Sun, Xiuhua
    Su, Liping
    Zhang, Huilai
    Lin, Zhijuan
    Yang, Haiyan
    Zhao, Weili
    Qiu, Lugui
    Li, Zhiming
    Song, Yuqin
    Xu, Bing
    BLOOD, 2023, 142